17 stories found
The article compares Royalty Pharma plc (RPRX) and AstraZeneca PLC (AZN) to determine which biopharma company offers a more promising growth story based on their respective business models.
AstraZeneca announced better-than-expected Q2 earnings, with sales significantly boosted by strong demand for its cancer treatments. The pharmaceutical giant also raised its interim dividend and reaffirmed its full-year 2026 guidance.
The potential for AstraZeneca PLC (AZN) to expand its rare disease portfolio through the Ultomiris expansion is being assessed.
Pharmaceutical giant AstraZeneca PLC announced robust financial results and raised its guidance, leading to a positive market reaction for its stock.
AstraZeneca PLC is presented as one of the best firms offering a combination of low risk and high growth potential in the market.
Morgan Stanley analysts project double-digit earnings per share (EPS) growth for AstraZeneca PLC (AZN), indicating a positive financial outlook for the pharmaceutical company.
Reports indicate Wall Street analysts are not convinced by recent discussions regarding a potential merger between AstraZeneca PLC and Bristol-Myers Squibb Company.
Several companies, including Brown & Brown, Amkor Technology, Rambus, Cincinnati Financial, Nucor, Cadence Design Systems, Baker Hughes, AstraZeneca PLC, Noble, Bank of Hawaii, and Coca-Cola FEMSA, have released their Q2 2026 earnings previews.
AstraZeneca PLC's stock experienced a decline after an FDA panel voted against the approval of its new cancer drug.
A series of financial articles provides analysis on whether various company stocks, including major players like Apple, Tesla, and Nvidia, represent good investment opportunities. These reports offer insights into potential buys in the current market.
Guggenheim has increased its price target for AstraZeneca PLC (AZN) shares from 16,000 GBp to 16,500 GBp.
Hedge funds are identifying Iovance Biotherapeutics Inc. (IOVA) and AstraZeneca PLC (AZN) as leading immunotherapy stocks to buy.
Hedge funds are reportedly showing a strong bullish sentiment towards AstraZeneca PLC (AZN).
AstraZeneca PLC (AZN) is highlighted as an attractive investment opportunity, primarily due to its robust growth profile and market positioning.
CDT Equity has advanced AstraZeneca PLC (AZN)’s compound AZD5904 into the Patent Cooperation Treaty (PCT) patent protection stage.
AstraZeneca PLC announced positive findings from a prespecified interim analysis of its I CAN Phase III clinical trial, indicating promising results for the studied treatment.
Guggenheim has increased its price target for pharmaceutical giant AstraZeneca PLC (AZN) from 15,500 GBp to 16,000 GBp, indicating a more optimistic outlook for the company's stock.